Marfan syndrome. MedDRA version: 14.1 Level: PT Classification code 10026829 Term: Marfan's syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders
Conditions
Interventions
Trade Name: Aprovel
Product Name: Aprovel
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Irbesartan
CAS Number: 38402-11-6
Sponsors
Clinical Trials and Research Governance
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Male or female, aged 13 years or above at last birthday (note that there is no upper age limit for inclusion in this trial) • For those aged greater than or equal to 16 years of age at the time of enrolment, participant is willing and, in the opinion of the investigator, able to give informed consent for participation in the trial • For those aged 13-15 at the time of enrolment, participant is willing and, in the opinion of the investigator, able to give informed assent, and parent/guardian is willing and able to give informed consent for participation in the trial. • Weight = 50kg • Diagnosed with Marfan syndrome according to the revised Ghent criteria 1996 • Dilated aorta (BSA-adjusted aortic root z-score =2 at the aortic sinuses of Valsalva, using the method of Roman et al, or an absolute aortic root dimension >4.0cm at the sinuses of Valsalva measured using either echocardiography or CMR) • If the participant is a female of child-bearing potential, they are willing to ensure effective contraception as defined in the contraception policy • If the participant is taking ß-blocker therapy, they are willing to stop taking these one week prior to each CMR scan • Willing and, in the investigator’s opinion, able to comply with all trial requirements • Willing to allow his or her General Practitioner and if appropriate, Consultant, to be informed of his or her participation in the trial and of any clinical findings or issues which may arise Are the trial subjects under 18? yes Number of subjects for this age range: 6 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 44 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 6
Exclusion criteria
Exclusion criteria: The potential participant may not enter the trial if ANY of the following apply: • Female who is pregnant • Female who is planning pregnancy within 6 months of enrolment • Female who is breast feeding • Previous aortic dissection • Previous aortic surgery • Bicuspid or unicuspid aortic valve • Scheduled elective cardiac or aortic surgery within 6 months of enrolment • Definite diagnosis of Loeys-Dietz or Shpritzen-Goldberg syndrome • Known bilateral renal artery stenosis or renal artery stenosis to a single functioning kidney • History of idiopathic intracranial hypertension • Exposure to angiotensin receptor antagonists, angiotensin converting enzyme inhibitors, or medications containing these compounds in the 3 months prior to enrolment in the trial • Absolute indication for angiotensin receptor antagonists, angiotensin converting enzyme inhibitors, doxycycline or other antibiotics of the tetracycline class at enrolment • Participant has participated in another research study involving an investigational medicinal product or device in the 3 months prior to enrolment • Renal impairment of a moderate or severe degree (eGFR 5.1 mmol/L) • Significant hepatic impairment (ALT or AST >3 times upper limit of normal) • History of allergic reaction or any other clinically significant intolerance to irbesartan or its constituents; other angiotensin receptor blockers / antagonists; angiotensin converting enzyme inhibitors, doxycycline or its constituents, or placebo medications or its constituents • Contra-indications to MRI (e.g. implantable cardiac electronic device, claustrophobia, intracranial aneurysm clips and metallic ocular foreign bodies etc.) • Participant currently required to take or likely to be required to start, in the 6 months following enrolment, a medicinal product which is known or suspected to interact, to a clinically significant extent, with irbesartan including: potassium supplementation, potassium sparing diuretics, lithium, regular use of antacids containing aluminium magnesium hydroxide • Participant currently required to take or likely to be required to start, in the 6 months following enrolment, a medicinal product which is known or suspected to interact, to a clinically significant extent, with doxycycline including ergotamine and methysergide. This includes drugs known to induce the cytochrome P450 system to a clinically significant extent, including but not limited to, carbamazepine, phenytoin, rifampicin, griseofulvin, barbiturates or sulphonylureas. • Alcohol dependence • Any other significant disease, disorder or circumstance (e.g. terminal illness), which, in the opinion of the Investigator, may either put the participant at risk in the trial, or may introduce significant bias to the trial, or may affect the participant’s ability to participate in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: In patients with the Marfan syndrome and enlargement of the aorta: 1) To estimate the effects of allocation to these treatment strategies on: i. the size of the aorta ii. the size and function of the heart iii. blood test measures relevant to the Marfan syndrome 2) To explore the safety and tolerability of irbesartan, of doxycycline and of a combination of both, compared to placebo. The trial is not intended to definitively evaluate these clinical outcomes. 3) To explore the effect of irbesartan, of doxycycline and of a combination, on short-term rates of tearing of the aorta, death from cardiovascular cause, or need for cardiovascular surgery, compared to placebo. The trial is not intended to definitively evaluate these clinical outcomes ;Main Objective: The primary objective of the trial is to estimate the effects of allocation to irbesartan, or doxycycline, or a combination of both irbesartan and doxycycline, compared with placebo, on measures of elastic function of the aorta in people with the Marfan syndrome and enlargement of the aorta.;Primary end point(s): Change (i.e. difference between first and last study visits) in aortic distensibility in the ascending aorta between allocation arms measured using CMR ; Timepoint(s) of evaluation of this end point: Time point 1: study entry Time point 2: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary Endpoints: 1. Change in aortic distensibility in the proximal and distal descending aorta between allocation arms measured using CMR 2. Change in aortic dimensions in the proximal and distal descending aorta 3. Change in mean and peak axial and mean and peak circumferential aortic wall shear stress between allocation arms estimated by CMR using a 4D flow sequence 4. Change in peripheral (brachial) blood pressure between allocation arms measured using a calibrated, validated automated sphygmomanometer 5. Change in central blood pressure, and augmentation index between allocation arms measured by applanation tonometry and by oscillometric sphygmomanometry 6. Change in left ventricular volumes, mass and systolic function between allocation arms to placebo measured by CMR 7. Change in aortic pulse wave velocity between allocation arms measured by CMR 8. Change in carotid-femoral pulse wave velocity between allocation arms compared to placebo measured by applanation tonometry 9. Change in TGF-ß level or other circulating biomarkers between allocation arms compared to placebo 10. Tolerability and safety of irbesartan and doxycycline, assessed by incidence of adverse reactions and change in health status score, using the SF-36 questionnaire 11. Document the frequency of aortic dissection, death from cardiovascular causes, or need for aortic root or valve surgery (if any) in each allocation arm ; Timepoint(s) of evaluation of this end point: Time point 1: study entry Time point 2: 6 months | — |
Countries
United Kingdom
Outcome results
None listed